{rfName}
Ru

Indexed in

License and use

Citations

1

Altmetrics

Impact on the Sustainable Development Goals (SDGs)

Analysis of institutional authors

Mussetti AAuthor

Share

December 15, 2024
Publications
>
Article
No

Ruxolitinib in acute and chronic graft-versus-host disease: real life long-term experience in a multi-center study for adult and pediatric patients, on behalf of the GETH-TC.

Publicated to:Bone Marrow Transplantation. - 2024-12-11 (), DOI: 10.1038/s41409-024-02483-0

Authors: Virginia Escamilla Gómez; Valentín García‐Gutiérrez; Patricia Alcalde‐Mellado; Beatriz Astibia Mahillo; Anabelle Chinea; Lucía López‐Corral; Marina Acera-Gómez; M. A. Ochando; Asunción Borrero Borrego; Leslie González Pinedo; Teresa Zudaire; Marta González‐Vicent; Ana Benzaquén; Isabel Izquierdo; Pedro Asensi Cantó; Juan Montoro; Francisco Martín-Domínguez; Guillermo Ortí; David Valcárcel; María Isabel Benítez‐Carabante; Cristina Díaz de Heredia; Eloi Cañamero; Christelle Ferrá; Irene García‐Cadenas; Sara Redondo; Luisa Sisinni; Antonio Pérez‐Martínez; Alberto Mussetti; Lucía Garcia-Mañó; María Del Pilar Palomo-Moraleda; Pedro Antonio González Sierra; Manuel Jurado; José Antonio Pérez‐Simón

Affiliations

- Author
Department of Hematology, Hospital Clínico Universitario de Salamanca (CAUSA/IBSAL), Salamanca, Spain. - Author
Department of Hematology, Hospital Duran i Reynals, Instituto Catalán de Oncología, L'Hospitalet De Llobregat, Barcelona, Spain. - Author
Hemato-Oncology Pediatric Service, HospitalUniversitario La Paz, Madrid, Spain. - Author
Hematology and Oncology Department, Division of Pediatric Hematology and Oncology, Hospital Universitario Vall d´Hebron, Barcelona, Spain. - Author
Hematology Deparment, HospitalUniversitario Germans Trias i Pujol - Institut Català d'Oncologia, Barcelona, Spain. - Author
Hematology Department, Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria INCLIVA, Valencia, Valencia, Spain. - Author
Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. - Author
Hematology Department, Hospital Universitario Central de Asturias, Oviedo, Spain. - Author
Hematology Department, Hospital Universitario de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain. - Author
Hematology Department, Hospital Universitario de Navarra, Pamplona, Spain. - Author
Hematology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain. - Author
Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain. - Author
Hematology Department, HospitalUniversitario Vall d´Hebron, Barcelona, Spain. - Author
Hematology Service, Hospital Universitario Ramón y Cajal. IRYCIS, Universidad de Alcalá, Madrid, Spain. - Author
Hematology Service, Hospital Universitario Ramón y Cajal. IRYCIS, Universidad de Alcalá, Madrid, Spain. jvalentingg@gmail.com. - Author
Hematopoietic Transplant Department, Hospital Universitario Niño Jesús, Madrid, Spain. - Author
Hospital Universitario Son Espases, Islas Baleares, Spain. - Author
Hospital Universitario Virgen de las Nieves, Instituto de Investigación Biosanitaria, Granada, Spain. - Author
Servicio de hematologia, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain. - Author
Servicio de hematologia, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain. josea.perez.simon.sspa@juntadeandalucia.es. - Author
See more

Abstract

Ruxolitinib has been approved for the treatment of adults and pediatric patients ≥12 years with steroid refractory graft-versus-host disease (GvHD). However, real-life studies are needed to confirm the results of clinical trials and further assess its efficacy in special populations. We performed a descriptive, retrospective, multi-center study of 352 adults and 42 pediatric patients treated with ruxolitinib for steroid-refractory acute or chronic GvHD. Among 119 and 233 adult patients with acute and chronic GvHD, overall response rate (ORR) was 58.8% (CR 33.6%) and 65.7% (CR 18.5%), respectively. Corticosteroids were withdrawn in 59.2% and 40.1%, and ruxolitinib in 47.2% and 34.8% in the acute and chronic groups of responders. Among 29 and 13 pediatric patients with acute and chronic GvHD, ORR was 82.7% (CR 51.7%) and 100% (CR 23%), respectively. Among responder patients, corticosteroids were withdrawn in 72.7% and 50%, and ruxolitinib in 75% and 30.7% in both groups respectively. Ruxolitinib in the real world setting, showed similar results as compared to clinical trials. Its efficacy is maintained in subsequent lines of treatment. In the pediatric population, the data are more favorable. In the long-term follow-up, corticosteroids, ruxolitinib and other inmunosuppressive drugs could be eliminated in a remarkably proportion of patients.

Keywords

Zero hunger

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Bone Marrow Transplantation due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position 61/181, thus managing to position itself as a Q1 (Primer Cuartil), in the category Immunology.

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-08-12:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 11.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 9 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 5.85.
  • The number of mentions on the social network X (formerly Twitter): 11 (Altmetric).
Continuing with the social impact of the work, it is important to emphasize that, due to its content, it can be assigned to the area of interest of ODS 2 - Zero hunger, with a probability of 42% according to the mBERT algorithm developed by Aurora University.

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Granada.